- Trials with a EudraCT protocol (2,062)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
2,062 result(s) found for: Drug clearance.
Displaying page 10 of 104.
EudraCT Number: 2005-001596-34 | Sponsor Protocol Number: CLL2M | Start Date*: 2006-04-10 |
Sponsor Name:Universität zu Köln | ||
Full Title: Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia | ||
Medical condition: previously untreated or relapsed chronic lymphocytic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005738-12 | Sponsor Protocol Number: LIPSTIC.V.01 | Start Date*: 2013-03-27 |
Sponsor Name:Alder Hey Children's NHS Foundation Trust | ||
Full Title: Liverpool Pharmacokinetic/pharmacodynamics study of teicoplanin in children (LIPSTIC). | ||
Medical condition: Gram-positive bacterial infection: late-onset neonatal sepsis, central line-associated blood stream infection, ventilator-associated pneumonia. | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004280-31 | Sponsor Protocol Number: 04/280507 | Start Date*: 2006-02-02 |
Sponsor Name:University of Dundee | ||
Full Title: Hyperthermic Intraperitoneal Chemotherapy - Gastric Cancer | ||
Medical condition: Gastric Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018373-38 | Sponsor Protocol Number: RG_09-071 | Start Date*: Information not available in EudraCT |
Sponsor Name:University of Birmingham | ||
Full Title: A Phase I trial of figitumumab, an IGF-1R antibody, in children aged 1-12 years old with relapsed/refractory Solid Tumours | ||
Medical condition: Paediatric patients aged 1-12 years with relapsed / refractory solid tumours. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: FR (Ongoing) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004137-27 | Sponsor Protocol Number: ScanCLAD_1.0(formerVersion_0.1) | Start Date*: 2016-05-19 |
Sponsor Name:Transplantationscentrum, Sahlgrenska Universitetssjukhuset | ||
Full Title: A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysf... | ||
Medical condition: Recipients of primary bilateral lung transplant allograft | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002728-35 | Sponsor Protocol Number: HUN-AVI-01 | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium | |||||||||||||
Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study − | |||||||||||||
Medical condition: Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test with mild pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001178-13 | Sponsor Protocol Number: NMSG#24/15 | Start Date*: 2017-02-02 | |||||||||||
Sponsor Name:Helsinki University Central Hospital | |||||||||||||
Full Title: Phase 2 study of carfilzomib + elotuzumab + dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines | |||||||||||||
Medical condition: Multiple myeloma patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001532-11 | Sponsor Protocol Number: 01apr2014 | Start Date*: 2014-09-11 |
Sponsor Name:Ospedale San Raffaele | ||
Full Title: MONO-INSTITUTIONAL PHASE II TRIAL ADDRESSING TOLERABILITY AND ACTIVITY OF R-CHOP CHEMOIMMUNOTHERAPY PRECEDED BY BLOOD-BRAIN BARRIER PERMEABILIZATION BY NGR-TUMOR NECROSIS FACTOR IN PATIENTS WITH RE... | ||
Medical condition: Primary non-Hodgkin lymphoma in the central nervous system relapse / refractory | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004460-22 | Sponsor Protocol Number: 5012005 | Start Date*: 2006-05-12 |
Sponsor Name:Hopital Erasme | ||
Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo n... | ||
Medical condition: focal and segmental glomerulosclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004469-40 | Sponsor Protocol Number: 5022005 | Start Date*: 2006-05-12 |
Sponsor Name:Hopital Erasme | ||
Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndro... | ||
Medical condition: Membranous Nephropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002095-93 | Sponsor Protocol Number: GS-US-236-0140 | Start Date*: 2014-09-24 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir p... | |||||||||||||
Medical condition: Human Immunodeficiency Virus, Type 1 (HIV-1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) ES (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000754-38 | Sponsor Protocol Number: TMC114FD2HTX3001 | Start Date*: 2015-08-19 | |||||||||||
Sponsor Name:Janssen Sciences Ireland UC | |||||||||||||
Full Title: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combinatio... | |||||||||||||
Medical condition: Human Immunodeficiency Virus Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000451-41 | Sponsor Protocol Number: HO150 | Start Date*: 2019-03-01 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therap... | ||||||||||||||||||
Medical condition: AML or MDS-EB2 with a mutation in either IDH1 or IDH2 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) FI (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002443-28 | Sponsor Protocol Number: ACE-CL-311/D8221C00001 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:Acerta Pharma B.V. | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investiga... | |||||||||||||
Medical condition: Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) HU (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003414-12 | Sponsor Protocol Number: HDP-101-01 | Start Date*: 2021-09-09 | |||||||||||
Sponsor Name:Heidelberg Pharma AG | |||||||||||||
Full Title: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma Cell Disorders Including Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or refractory Multiple Myeloma (r/r MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004914-79 | Sponsor Protocol Number: CA017-003 | Start Date*: 2016-10-22 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors | |||||||||||||
Medical condition: Advanced Malignant Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008262-12 | Sponsor Protocol Number: GFM-Len-Epo-08 | Start Date*: 2009-10-05 | |||||||||||
Sponsor Name:Groupe Francophone des Myélodysplasies | |||||||||||||
Full Title: A phase II study evaluating the efficacy and safety of Lenalidomide (Revlimid®) with or without Epoetin beta (NeoRecormon®) in transfusion-dependent ESA-resistant patients with IPSS low- and interm... | |||||||||||||
Medical condition: patients with IPSS low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormality | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001268-44 | Sponsor Protocol Number: MDCO-CLV-12-01 | Start Date*: 2013-09-10 |
Sponsor Name:Chiesi USA, Inc. | ||
Full Title: Open label study to assess the efficacy, safety and dosing of clevidipine in pediatric patients undergoing surgery. | ||
Medical condition: Blood pressure management in pediatric patients in the perioperative setting. Treatment of hypertensive patients and normotensive patients who require lowering of blood pressure for the procedure. | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-004623-36 | Sponsor Protocol Number: MEGALiT1901 | Start Date*: 2019-11-29 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial – a multicenter, basket and umbrella explorative trial on the efficacy and safety of molecular profile selected commercially available targete... | ||
Medical condition: In part 1 of the study: any solid tumor with the exemption of sarcoma. In part 2: any solid tumor or hematological malignancy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004108-16 | Sponsor Protocol Number: HOFATA_v3.0 | Start Date*: 2022-04-21 |
Sponsor Name:Medical University Vienna | ||
Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study | ||
Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
